

# Type 2 Angiotensin II Receptor - Pipeline Review, H1 2020

<https://marketpublishers.com/r/T9CF6C2543E3EN.html>

Date: April 2020

Pages: 55

Price: US\$ 3,500.00 (Single User License)

ID: T9CF6C2543E3EN

## Abstracts

Type 2 Angiotensin II Receptor - Pipeline Review, H1 2020

### SUMMARY

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Type 2 Angiotensin II Receptor - Pipeline Review, H1 2020, outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis.

The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 3, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from

therapy areas Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Respiratory, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Metabolic Disorders, Musculoskeletal Disorders, Oncology and Women's Health which include indications Idiopathic Pulmonary Fibrosis, Atherosclerosis, Cardiomyopathy, Coronavirus Disease 2019 (COVID-19), Diabetic Neuropathic Pain, Fibrosis, Hyperlipidemia, Hypertension, Inflammatory Pain, Kidney Fibrosis, Liver Fibrosis, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Polycystic Ovarian Syndrome, Postherpetic Neuralgia, Skin Inflammation, Systemic Sclerosis (Scleroderma) and Wounds.

Furthermore, this report also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)

The report reviews Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics and enlists all

their major and minor projects

The report assesses Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Overview

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) -

Companies Involved in Therapeutics Development

CJ HealthCare Corp

KinDex Pharmaceuticals Inc

MorphoSys AG

Novartis AG

Novopyxis Inc

Vicore Pharma AB

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles

(amlodipine besylate + valsartan) + atorvastatin calcium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KDT-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOR-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-6A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olodanrigan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain -  
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize AGTR2 for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and  
Myocardial Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VP-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VP-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant  
Products

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) -  
Discontinued Products

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Product  
Development Milestones

Featured News & Press Releases

Mar 31, 2020: Vicore Pharma submits Letter of Intent for a clinical trial application for a  
phase II study in patients with COVID-19, SARS CoV-2 infection

Mar 30, 2020: Vicore submits clinical trial application for phase II trial with C21 in IPF

Dec 18, 2019: Update on progress for drug development program VP02 (IMiD)

Dec 18, 2019: Update on progress for drug development program VP01 (C21)

Oct 01, 2019: Update on progress in clinical lead program VP01 (C21)

Sep 06, 2019: Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study

Apr 23, 2019: Vicore Pharma announces systemic sclerosis as the second indication for VP01

Sep 10, 2018: Vicore Pharma expands VP01 (C21) clinical program to enable functional read out

Jul 05, 2018: Non-opioid drug relieves pain in mice, targets immune cells

Apr 18, 2018: Vicore Pharma receives approval to start Phase IIa study in IPF

Mar 21, 2018: Frontiers in Physiology publish data with C21 on pulmonary fibrosis

Jan 26, 2018: Highlights from new publications on C21 and the AT2 receptor

Dec 22, 2017: Vicore Pharma has submitted an application to start a phase II study for Idiopathic Pulmonary Fibrosis

Oct 09, 2017: Clinical Potential of C21 Highlighted in Review Publications

Oct 02, 2017: Phase I extension study demonstrates beneficial effects on lipid metabolism with C21

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Indication, H1 2020  
Number of Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020  
Number of Products under Investigation by Universities/Institutes, H1 2020  
Products under Investigation by Universities/Institutes, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Pipeline by CJ HealthCare Corp, H1 2020  
Pipeline by KinDex Pharmaceuticals Inc, H1 2020  
Pipeline by MorphoSys AG, H1 2020  
Pipeline by Novartis AG, H1 2020  
Pipeline by Novopyxis Inc, H1 2020  
Pipeline by Vicore Pharma AB, H1 2020  
Dormant Products, H1 2020  
Dormant Products, H1 2020 (Contd..1), H1 2020  
Discontinued Products, H1 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

CJ HealthCare Corp

KinDex Pharmaceuticals Inc

MorphoSys AG

Novartis AG

Novopyxis Inc

Vicore Pharma AB

## I would like to order

Product name: Type 2 Angiotensin II Receptor - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/T9CF6C2543E3EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T9CF6C2543E3EN.html>